Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Translating Individual-level Risks and Preferences Into Personalized Blood Pressure Target Decisions

Award Number: K23HL173670
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP
PERIOD OF PERFORMANCE START DATE: 02/01/2025
PERIOD OF PERFORMANCE END DATE: 01/31/2030

Group Awards By:

View Award Description

Translating Individual-level Risks and Preferences Into Personalized Blood Pressure Target Decisions - PROJECT SUMMARY Simon Ascher, MD, MPH is establishing himself as a clinical investigator in patient-oriented research that focuses on individualizing clinical decision-making in hypertension. This K23 award will provide the necessary training for Dr. Ascher to successfully transition to an independent investigator and achieve the following goals: 1) develop expertise in advanced statistical methods for predicting individualized treatment effects from clinical trials; 2) acquire essential knowledge and skills in using surveys to quantify patient preferences; 3) obtain hands-on experience in developing patient decision aids embedded in the electronic health record (EHR); and 4) gain proficiency in designing and conducting behavioral clinical trials. Dr. Ascher has assembled a mentorship team led by his co-primary mentors, Dr. Richard Kravitz, an established leader in doctor-patient communication and heterogeneous treatment effects; and Dr. Michael Shlipak, an internationally renowned researcher in kidney and cardiovascular disease epidemiology, and comprised of co-mentors and advisors who provide complementary expertise in advanced biostatistics methods, health preferences, digital health, and clinical trials. Hypertension affects nearly half of all U.S. adults, yet optimal blood pressure (BP) targets continue to be heavily debated and poorly implemented. The Systolic Blood Pressure Intervention Trial (SPRINT) demonstrated among non-diabetic individuals that intensive BP treatment reduces CVD events and deaths, but also increases serious adverse events. The broad application of SPRINT could have enormous public health impact, but well-documented heterogeneity in risks and preferences requires individualized decision-making. Building on Dr. Ascher's KL2-supported work, the current proposal aims to develop a personalized approach to BP targets by combining several powerful strategies: individualized risk prediction for multiple outcomes, calibration of the benefits and harms from BP treatment according to patient preferences, and use of a BP target decision aid to guide shared decision-making. In Aim 1, he will refine models in SPRINT that predict for each outcome an individual's change in absolute risk with intensive versus standard BP lowering and then seek external validation in the Action to Control Cardiovascular Risk in Diabetes Blood Pressure (ACCORD BP) trial. In Aim 2, he will use an instrument he previously developed to characterize the variation in patient preferences for BP treatment outcomes, and to identify a limited set of patient clusters with similar preferences. In Aim 3, he will first develop an interactive BP target decision aid embedded in the EHR that translates a patient's risks and preferences into a personalized BP target recommendation; he will then evaluate the decision aid's feasibility in a pilot trial. The proposed plans are realistic and feasible within the 5- year award period, and will lay the groundwork to pursue funding to conduct a large-scale trial of the BP target decision aid. In addition, Dr. Ascher will have acquired the skills and experience necessary to achieve his career goal of becoming a leader and innovator in efforts to individualize CVD prevention strategies.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $191,856 )
2026	2026	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR STE 300	DAVIS	CA	95618	YOLO	USA	Cardiovascular Diseases Research	000	2	3/6/2026	NON-COMPETING CONTINUATION	$191,856
														Subtotal = $191,856

Issue Date FY: 2025 ( Subtotal = $191,777 )
2025	2025	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR STE 300	DAVIS	CA	95618	YOLO	USA	Cardiovascular Diseases Research	000	1	1/24/2025	NEW	$191,777
														Subtotal = $191,777

Grand Total All Awards = $383,633

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Translating Individual-level Risks and Preferences Into Personalized Blood Pressure Target Decisions

Award Number: K23HL173670

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP

PERIOD OF PERFORMANCE START DATE: 02/01/2025

PERIOD OF PERFORMANCE END DATE: 01/31/2030

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer